Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Approvals Europe Value-Added Medicines

Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin

Launch Imminent For ‘First Once-Daily Pregabalin Formulation’ Value Added Medicine

  • News

Executive Summary

Adalvo, the B2B unit of the Alvo group of companies, has announced a successful decentralized European approval for its pregabalin prolonged-release tablets, with a launch imminent. The “milestone” for its value added medicines program could allow the firm to offer what it has previously billed as “the first once-daily pregabalin formulation.”

Table

View full table

Topics

Related Companies

Tags:
Approvals Europe Value-Added Medicines
Latest Headlines

Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results

Lupin Enters Canadian Biosimilars Market With Etanercept

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

See All
UsernamePublicRestriction

Register

GB153203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By